Targeting Non-Replicating Mycobacterium tuberculosis and Latent Infection: Alternatives and Perspectives (Mini-Review)

Latent tuberculosis infection (LTBI) represents a major challenge to curing TB disease. Current guidelines for LTBI management include only three older drugs and their combinations—isoniazid and rifamycins (rifampicin and rifapentine). These available control strategies have little impact on latent...

Descripción completa

Detalles Bibliográficos
Autores principales: Egorova, Anna, Salina, Elena G., Makarov, Vadim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707483/
https://www.ncbi.nlm.nih.gov/pubmed/34948114
http://dx.doi.org/10.3390/ijms222413317

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707483/
https://www.ncbi.nlm.nih.gov/pubmed/34948114
http://dx.doi.org/10.3390/ijms222413317

Ejemplares similares